Gunderson Dettmer client TScan Therapeutics, an immunotherapy company for blood cancers, announced it had entered into a licensing and collaboration agreement with Novartis.

In a story about the agreement TScan Chief Scientific Officer Gavin MacBeath, Ph.D., said “When we discover a new target, we simultaneously discover the TCR that recognizes that target, so we lump target discovery and therapeutic discovery into one process.” With each hit, the company immediately has leads that can be pushed toward the clinic—“an aspect that really captured Novartis’ attention.”

The Gunderson deal team was led by partner Brendan McCarthy and included Tim Ehrlich and Brittany Nicely.